Angelman Syndrome: How late is too late for treatment?

Experiments on mice suggest that an approach called antisense oligonucleotide therapy may be able to treat some symptoms of Angelman syndrome, including problems with epilepsy and sleep.
  1. Lawrence T Reiter  Is a corresponding author
  1. Department of Neurology, Department of Pediatrics, Department of Anatomy and Neurobiology, College of Medicine, University of Tennessee Health Science Center, United States

An approach called antisense oligonucleotide (ASO) therapy has ushered in a new age in genetic medicine. ASO therapy works by introducing a short strand of RNA that binds to specific messenger RNA (mRNA) molecules in the host, and thus prevents the mRNA from being translated. Clinical trials are currently under way to see if ASO therapy will work for various neurodevelopmental disorders, including Dravet syndrome (an epilepsy disorder), spinal muscular atrophy (a neuromuscular condition) and Batten’s disease (a devastating lysosomal storage disorder; Hill and Meisler, 2021).

Angelman syndrome is a neurodevelopmental disorder that is considered an ideal candidate for ASO therapy. Symptoms appear very early in childhood and include learning disabilities, abnormally happy demeanor, epilepsy, and difficulty controlling motor function, particularly while walking (Dagli et al., 1993). Children with Angelman syndrome also suffer from sleep problems. It has previously been shown, using cellular and animal models, that the regulation of a single gene, UBE3A, in the nervous system leads to the major features of Angelman syndrome (Kishino et al., 1997; Matsuura et al., 1997; Sutcliffe et al., 1997). UBE3A is found on chromosome 15, and most cases of Angelman syndrome are the result of a large deletion in the maternal copy of this chromosome. This means that most individuals have a working – but silent – paternal copy of UBE3A on chromosome 15. However, this copy is silenced by an antisense transcript which interferes with the expression of the paternal UBE3A.

Using ASO therapy to interfere with the antisense transcript – and thus allowing the intact copy of UBE3A to be expressed – is a promising approach for the treatment of Angelman syndrome. However, some scientists remain skeptical about the potential for ASO therapy to treat neurodevelopmental disorders, and several questions remain regarding how these treatments will work. For example, when does it become too late in human development to reactivate a missing gene in the nervous system? Are there neurogenetic diseases that can be rescued in adulthood? And, if so, what features of the disease can be treated with ASO therapies?

Extensive research has focused on answering these questions by reactivating the paternal copy UBE3A in a commonly used mouse model for Angelman syndrome. One goal of these studies has been to determine which symptoms can be reduced or eliminated. Another goal, which may be more challenging to achieve, is to establish when the gene should be reactivated during development in order to achieve the desired effect.

In 2018, researchers at the Erasmus Medical Center in Rotterdam published a set of behaviors that can be used to assess phenotypes for motor performance, repetitive behavior, anxiety, and seizure susceptibility using Ube3a maternal deficient mice (Sonzogni et al., 2018). These behaviors provide a framework to test the effectiveness of drugs (or ASOs) that reactivate the silent paternal copy of the gene. However, there are not many studies that dig deeper into the cognitive issues, sleep or epilepsy-related brain activity (as measured with EEG) that are known to be affected in this mouse model. Now, in eLife, Mingshan Xue and colleagues from Baylor College of Medicine and Ionis Pharmaceuticals – including Dongwon Lee, Wu Chen, Heet Naresh Kaku and Xinming Zhuo as first authors – report on the use of an ASO to rescue the characteristic EEG pattern and disordered sleep observed in a mouse model of Angelman syndrome (Lee et al., 2023).

First, Lee et al. designed a new Angelman syndrome mouse model that is less ‘leaky’ than the model used by other labs in previous studies – that is, a model where Ube3a expression from the maternal chromosome was more completely blocked. Then they injected the mice with an ASO against the Ube3a antisense transcript to see if the expression of the Ube3a protein could be rescued from the paternal chromosome. The results showed that, after injecting the mice with the ASO, the levels of Ube3a protein increased in multiple regions of the brain, including the cortex, the hippocampus and the hypothalamus, which controls sleep. Importantly, Ube3a expression was rescued in both juvenile and adult animals, which had previously been challenging.

Next, Lee et al. showed that the electrical activity in the brain of these mice is significantly rescued by injection of this ASO, in both juvenile and adult animals. They were also able to rescue the low level of rapid eye movement (REM) sleep observed in individuals with Angelman syndrome, with animals getting an almost normal amount of REM sleep six weeks after injection with the ASO.

The findings of Lee et al. illustrate that it may be possible to treat some aspects of Angelman syndrome after birth, and even into adulthood, using ASO therapeutics. This challenges the current view of what symptoms of Angelman syndrome are treatable, and at what age. While the delivery of ASOs to the brain is still a struggle, the latest results are encouraging for potential treatments for Angelman syndrome, and perhaps other neurodevelopmental disorders thought to be untreatable after birth.

References

  1. Website
    1. Dagli AI
    2. Mathews J
    3. Williams CA
    (1993) Angelman syndrome
    GeneReviews. Accessed February 2, 2023.

Article and author information

Author details

  1. Lawrence T Reiter

    Lawrence T Reiter is in the Department of Neurology, the Department of Pediatrics and the Department of Anatomy and Neurobiology, College of Medicine, University of Tennessee Health Science Center, Memphis, United States

    For correspondence
    lreiter@uthsc.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4100-2630

Publication history

  1. Version of Record published:

Copyright

© 2023, Reiter

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,977
    views
  • 65
    downloads
  • 1
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Lawrence T Reiter
(2023)
Angelman Syndrome: How late is too late for treatment?
eLife 12:e86117.
https://doi.org/10.7554/eLife.86117

Further reading

    1. Medicine
    2. Neuroscience
    Joanna Kosinska, Julian C Assmann ... Markus Schwaninger
    Research Article

    Monomethyl fumarate (MMF) and its prodrug dimethyl fumarate (DMF) are currently the most widely used agents for the treatment of multiple sclerosis (MS). However, not all patients benefit from DMF. We hypothesized that the variable response of patients may be due to their diet. In support of this hypothesis, mice subjected to experimental autoimmune encephalomyelitis (EAE), a model of MS, did not benefit from DMF treatment when fed a lauric acid-rich (LA) diet. Mice on normal chow (NC) diet, in contrast, and even more so mice on high-fiber (HFb) diet showed the expected protective DMF effect. DMF lacked efficacy in the LA diet-fed group despite similar resorption and preserved effects on plasma lipids. When mice were fed the permissive HFb diet, the protective effect of DMF treatment depended on hydroxycarboxylic receptor 2 (HCAR2) which is highly expressed in neutrophil granulocytes. Indeed, deletion of Hcar2 in neutrophils abrogated DMF protective effects in EAE. Diet had a profound effect on the transcriptional profile of neutrophils and modulated their response to MMF. In summary, DMF required HCAR2 on neutrophils as well as permissive dietary effects for its therapeutic action. Translating the dietary intervention into the clinic may improve MS therapy.

    1. Medicine
    2. Neuroscience
    Tomohiro Umeda, Ayumi Sakai ... Takami Tomiyama
    Research Article

    Neurodegenerative diseases are age-related disorders characterized by the cerebral accumulation of amyloidogenic proteins, and cellular senescence underlies their pathogenesis. Thus, it is necessary for preventing these diseases to remove toxic proteins, repair damaged neurons, and suppress cellular senescence. As a source for such prophylactic agents, we selected zizyphi spinosi semen (ZSS), a medicinal herb used in traditional Chinese medicine. Oral administration of ZSS hot water extract ameliorated Aβ and tau pathology and cognitive impairment in mouse models of Alzheimer’s disease and frontotemporal dementia. Non-extracted ZSS simple crush powder showed stronger effects than the extract and improved α-synuclein pathology and cognitive/motor function in Parkinson’s disease model mice. Furthermore, when administered to normal aged mice, the ZSS powder suppressed cellular senescence, reduced DNA oxidation, promoted brain-derived neurotrophic factor expression and neurogenesis, and enhanced cognition to levels similar to those in young mice. The quantity of known active ingredients of ZSS, jujuboside A, jujuboside B, and spinosin was not proportional to the nootropic activity of ZSS. These results suggest that ZSS simple crush powder is a promising dietary material for the prevention of neurodegenerative diseases and brain aging.